Investigating vancomycin levels in patients on CRRT with oXiris membrane
Pharmacokinetics of Vancomycin in Patients Receiving Continuous Veno-Venous Hemodiafiltration (CVVHDF) with the Absorptive OXiris Membrane
This study tests how the antibiotic vancomycin works in patients receiving a special type of kidney treatment called CRRT with an oXiris membrane to see if it affects the drug levels in their blood.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 8 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Mahidol University Academic / other |
| Locations | 1 site (Bangkok, Payathi) |
| Trial ID | NCT06543940 on ClinicalTrials.gov |
What this trial studies
This study examines how vancomycin behaves in patients undergoing continuous renal replacement therapy (CRRT) using the oXiris membrane, which is known to absorb inflammatory cytokines. It aims to measure the pharmacokinetics of vancomycin by drawing blood samples at various time points after drug administration. The study hypothesizes that the oXiris membrane may reduce vancomycin levels, similar to findings with other membranes. The results will help clarify the drug's behavior in this specific patient population.
Who should consider this trial
Good fit: Ideal candidates are adults over 18 years old admitted to the ICU who are receiving CRRT with the oXiris filter and have been administered vancomycin.
Not a fit: Patients with a history of vancomycin allergy, those expected to die within 24 hours, or those on other forms of dialysis will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could optimize vancomycin dosing in patients with acute kidney injury undergoing CRRT, improving treatment outcomes.
How similar studies have performed: While there is limited in vivo data on the oXiris membrane's effect on vancomycin, similar pharmacokinetic studies have shown promising results with other membranes.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients aged more than 18 years. * Admitted to the intensive care unit of Ramathibodi Hospital. * Under continuous renal replacement therapy (CRRT) with CVVHDF using oXiris filter. * Received vancomycin at least once after starting CRRT with CVVHDF using oXiris filter. * who have signed the informed consent document. Exclusion Criteria: * Patients with a history of vancomycin allergy. * Patients expected to die within 24 hours after inclusion in study. * Patients with circuit clotting occurring more than 2 hours during the blood draw period. * Patients treated with extracorporeal membrane oxygenation (ECMO). * Patients with a history of kidney transplantation. * Pregnant or breastfeeding women. * Patients who have decided to receive palliative care. * Patients on hemodialysis or peritoneal dialysis.
Where this trial is running
Bangkok, Payathi
- Facullty of Pharmacy Mahidol University — Bangkok, Payathi, Thailand (Recruiting)
Study contacts
- Study coordinator: chidtawan Hirunsomboon, PharmD
- Email: chidtawan.hir@mahidol.ac.th
- Phone: +66-988309558
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.